“减肥药”，史诗级暴跌！

Core Viewpoint - Viking Therapeutics experienced a significant stock drop of nearly 44%, marking its largest intraday decline since April 2016, following disappointing mid-term trial data for its oral weight loss drug VK2735 [2][5]. Group 1: Viking Therapeutics - The mid-term trial data for VK2735 indicated that patients could lose up to 12.2% of their weight, with 80% of participants reporting a weight loss exceeding 10% [5]. - However, approximately 28% of patients withdrew from the trial within three months, raising concerns about the drug's competitiveness against offerings from Eli Lilly and Novo Nordisk [6]. - In contrast, last year, Viking Therapeutics reported positive results from the second phase of VK2735 trials, where patients on weekly doses lost an average of 14.7% of their weight after 13 weeks [6]. Group 2: Eli Lilly - Eli Lilly's oral weight loss drug Orforglipron showed positive results in its phase three clinical trial, with participants losing an average of 12.4 kg (approximately 12.4%) after 72 weeks [9]. - Following the announcement of Orforglipron's results, Eli Lilly's stock fell over 14%, resulting in a market cap loss of about $100 billion [10]. - Despite the initial drop, analysts believe the sell-off was an overreaction, as Eli Lilly's core growth drivers remain strong, and Orforglipron has significant global market potential [10].